Home
 »  Community
 »  Blogs
Doris' Blog

Putting c-peptide in insulin products


Doris' Blog
By: dorisjdickson


<< December 2008 >>
SunMonTueWedThuFriSat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31

 Blog Entries
Islet Cells Generation - Cure? I Think Not! - Oct 01
This article in Diabetes Health discusses yet another new potential "cure."  However, yet again, it requires immunosuppressants which are not an option to me.  ...
more
Cholesterol Conundrum - Sep 21
I recently wrote about Red Yeast Rice as an alternative to statins and the fact that it actually IS a statin since they contain the same active ingredients.  You just ...
more
Red Yeast Rice - It is a Statin - Do I Take It? - Sep 10
I receive Dr. Mercola's newsletter regularly.  I don't, however, regularly read it.  My concern is the amount of "stuff" sold on the website.  However, this ...
more
Diabetic ketoacidosis at onset of type 1 diabetes remains frequent in children - Sep 08
This article in yesterday's edition of Endocrine Today makes me scratch my head.  First and foremost, had this study been conducted in 1976 in the US and not in Germany, ...
more
Inaccurate Monitors and Strips - Sep 02
Some of you may have read about the FDA's recent warning about the inaccuracy of certain test strips while taking certain medications.  Honestly, I didn't pay much attention ...
more
Posted: Dec 31, 2008 15:21
  • 0 Comments.
  • Putting c-peptide in insulin products

    Diabetes blogger, Allie Beatty, wrote this week nearly screaming that type 1 diabetics should be lobbying the FDA to force insulin manufacturers to incorporate c-peptide into analog insulin products.  Her stance is that people who do not have diabetes do not have complications because they have c-peptide.  She cites a highly technical document in a 2007 issue of Diabetologia as her source and she seems to be almost dismissive of the role of higher than normal blood sugar as a cause of complications.  Her blog includes specific instructions to contact the FDA if anyone is interested.

     

    I had heard of the lack of c-peptide in analog insulin products prior to this blog.  “Talking” it through with other diabetics, we realized that 1) humulin products do not have c-peptides either but that 2) beef and pork insulin probably did since it came from animals not a “dish in a lab.”  I think we were assuming animals have c-peptide in their insulin.  We did not go much further with the discussion and I had long forgotten about he subject. 

     

    However, after reading Allie’s blog, I started reading the article she had attached.  It is quite technical, so I am sure I did not entirely understand it.  However, there is a basic assumption that is clearly in English that gives me cause to disagree with the analysis, at least until they are comparing apples to apples.  They say: 

     

    The DCCT study demonstrated a decreased occurrence of complications in the group of type 1 diabetes patients that received intensive insulin therapy and achieved improved blood glucose control, in keeping with the view that hyperglycemia is a major culprit in the pathogenesis of microvascular complications. Even though blood glucose levels were close to normal in the group that received intensive treatment, a large proportion of these patients still developed complications: 40% presented with clinical neuropathy or grossly abnormal nerve conduction after 5 years [43], and a similar fraction had developed signs of nephropathy or retinopathy. This suggests that factors in addition to hyperglycemia may be involved in the development of microvascular complications in type 1 diabetes patients. In view of the data for C-peptide described above, we suggest that lack of C-peptide contributes to the pathogenesis of complications of type 1 diabetes.

     

    What they neglect to say is that the DCCT trial blood sugar targets were NOT even close to normalized, non-diabetic blood sugar numbers.  Non-diabetic A1Cs are 4.2 – 4.6 and average blood sugar is in the 85 range.  The DCCT trials started before most of us even thought of targeting A1Cs of 5.0 or even closer to blood sugar.  Their study population therefore could never have achieved “close” to normal blood sugar.

     

    In fact, according to a January 2008 article in Diabetes Self-Management, “In actuality they achieved a median HbA1c of 7.2%.”  This “actuality” is nowhere close to “normal;” so it should be no big surprise that “a large proportion of these patients still developed complications.”  An A1C of 7.2 is >50% higher than a (healthy, thin) non-diabetic A1C.  How could that NOT cause complications?

     

    So, that leaves me with two thoughts:  1) How can we judge whether the lack of c-peptide is very important if researchers are not comparing apples to apples?  Why don’t they consider studying those of us who target and attain closer to normalized blood sugar?  2) Is it even possible to add c-peptide into humulin and/or analog insulin products?  (I see no reference to this possibility.  There is not much need to lobby the FDA without knowing this.)   If it is possible to add c-peptide to insulin products, is it cost effective (to the insurer or the diabetic)?  Does it have to be a separate, secondary injection, unit for unit?  Again, at what cost? 

     

    Now, keep in mind, I am often on the FDA bashing bandwagon.  However, this time, I think we best do some more homework and get back to the basic KNOWN cause of diabetes complications – non-normalized blood sugar – before we look for yet again, another, hugely expensive “complication alleviator.”

     

    Doris J. Dickson

     

     

     

     

    Comments (0):
  • Add Comment


  • Tags:

    Related posts:

  • Previous Blog Post
  • Next Blog Post
  • Glory Enough For All
    Glory Enough For All
    This video is the first segment of Glory Enough For All, a made-for-television ...
    more more Featured Videos
    Cost Savings Tool
    Do you know the annual cost of managing your diabetes? Would you like to find ways to reduce your costs? Calculate your total budget and identify ways to save money. You can do this in just a few minutes by entering facts about the products you use. This quick analysis will provide you with a comprehensive overview of both spending and potential savings.

    Cost Savings Tool
    Monitor Comparison Tools
    Blood glucose monitors offer an easy way to test your blood sugar at home or on the go. Use this comparison tool as a guide to learn more about the features and benefits of your current monitor or to find a new one.
    Handheld Monitor Comparison
    Continuous Glucose Monitor Comparison
    Advanced BMI Calculator
    Ever wonder if you are at a healthy weight? Then enter your height and weight in our advanced Body Mass Index (BMI) calculator. This tool provides you with two important numbers reflecting the estimated impact of your present body weight and shape upon your overall health.
    Advanced BMI Calculator
    more Care Tools
    Home | About Us | Press | Make a Suggestion | Content Syndication | Terms of Service | Editorial Policy | Privacy Policy
    Last updated: Dec 10, 2019  © 2019 Body1 All rights reserved.